Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$17,500.00

Therapeutic Neutralization of Platelet-derived Angiostatin to Promote Angiogenesis

FY 2014-15

Summary
Suppression of Angiostatin to Promote Therapeutic Angiogenesis Coronary artery disease (CAD) and peripheral artery disease (PAD) are currently leading causes of cardiovascular death worldwide. So far, one focus of therapies being developed includes promoting blood vessel growth (angiogenesis) to increase oxygen supply to ischemic tissues. This has been primarily done by supplying angiogenesis promoting proteins (such as vascular endothelial growth factor), genes, or cell-based therapies. However, these clinical trials have not had promising results and new therapeutic approaches are needed. Little consideration has been given to reducing endogenous factors that prevent new blood vessel growth. Our lab has studied the activity of a protein released by platelets called angiostatin. Angiostatin acts to prevent blood vessel growth specifically in a low oxygen environment that is characteristic of CAD and PAD. In fact, it has been shown that patients with CAD have elevated levels of angiostatin. Our objective is to suppress this factor thereby stopping its negative effects on angiogenesis. I plan to test the hypothesis that an angiostatin decoy receptor will neutralize angiostatin and promote an environment suitable for blood vessel growth. This decoy receptor will be tested on endothelial cells exposed to physiological concentrations of angiostatin under hypoxic conditions as well as in mouse models of hind limb ischemia and myocardial infarction. If successful, this would be a potential novel therapy for further preclinical development that focuses on bringing balance back to the vascular system, and improving its ability to re-oxygenate areas with low blood supply thereby improving morbidity and mortality of CAD/PAD patients.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
331549
Name
Govindasamy Natasha
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Therapeutic Neutralization of Platelet-derived Angiostatin to Promote Angiogenesis
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Innovative; Novel; Relevent; Therapeutic
Abstract
Suppression of Angiostatin to Promote Therapeutic Angiogenesis Coronary artery disease (CAD) and peripheral artery disease (PAD) are currently leading causes of cardiovascular death worldwide. So far, one focus of therapies being developed includes promoting blood vessel growth (angiogenesis) to increase oxygen supply to ischemic tissues. This has been primarily done by supplying angiogenesis promoting proteins (such as vascular endothelial growth factor), genes, or cell-based therapies. However, these clinical trials have not had promising results and new therapeutic approaches are needed. Little consideration has been given to reducing endogenous factors that prevent new blood vessel growth. Our lab has studied the activity of a protein released by platelets called angiostatin. Angiostatin acts to prevent blood vessel growth specifically in a low oxygen environment that is characteristic of CAD and PAD. In fact, it has been shown that patients with CAD have elevated levels of angiostatin. Our objective is to suppress this factor thereby stopping its negative effects on angiogenesis. I plan to test the hypothesis that an angiostatin decoy receptor will neutralize angiostatin and promote an environment suitable for blood vessel growth. This decoy receptor will be tested on endothelial cells exposed to physiological concentrations of angiostatin under hypoxic conditions as well as in mouse models of hind limb ischemia and myocardial infarction. If successful, this would be a potential novel therapy for further preclinical development that focuses on bringing balance back to the vascular system, and improving its ability to re-oxygenate areas with low blood supply thereby improving morbidity and mortality of CAD/PAD patients.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Govindasamy, Natasha
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~